尼日利亚东北部迈杜古里服用抗精神病药物的精神分裂症谱系障碍患者中性功能障碍的发生率及其相关因素。

IF 1.1 4区医学 Q4 PSYCHIATRY

International Journal of Psychiatry in Medicine Pub Date : 2024-05-01 Epub Date: 2023-08-24 DOI:10.1177/00912174231196612

Falmata Baba Shettima, Musa Abba Wakil, Taiwo Lateef Sheikh, Mohammed Abdulaziz, Isa Bukar Rabbebe, Ibrahim Abdu Wakawa, Ogualili Placidus

{"title":"尼日利亚东北部迈杜古里服用抗精神病药物的精神分裂症谱系障碍患者中性功能障碍的发生率及其相关因素。","authors":"Falmata Baba Shettima, Musa Abba Wakil, Taiwo Lateef Sheikh, Mohammed Abdulaziz, Isa Bukar Rabbebe, Ibrahim Abdu Wakawa, Ogualili Placidus","doi":"10.1177/00912174231196612","DOIUrl":null,"url":null,"abstract":"Objectives: Despite the importance of a satisfying sexual life, most patients with schizophrenia spectrum disorders do not discuss sexual issue with their clinicians. The current study seeks to determine the prevalence and socio-clinical correlates of sexual dysfunction among patients with schizophrenia spectrum disorders receiving typical and atypical antipsychotic medications. The second objective is to determine the frequency and correlates of specific sexual dysfunction (desire, arousal, erection/lubrication and orgasm) by gender and drug type using the Arizona Sexual Experience Scale.Methodology: This cross-sectional study used standardized structured interviewer based survey to assess sexual dysfunction among patients with schizophrenia that are both sexually active and inactive at a tertiary hospital in Maiduguri from December 2020 to April 2021. Participants were also assayed for prolactin using ELISA Kit for a possible association with sexual dysfunction.Results: The overall prevalence of sexual dysfunction among patients with schizophrenia spectrum disorder receiving antipsychotics was 34% with patients on typical and atypical antipsychotics reporting rates of 36.8% and 24.6%, respectively. Among the typical and atypical antipsychotics, patients receiving haloperidol (40.3%) and risperidone (37.5%) reported a relatively higher frequency of sexual dysfunction compared to those receiving clozapine (18.2%). Independent correlates of sexual dysfunction were: female gender (OR = 1.89, 95% CI = 1.17-3.06; P = .010), being unmarried (OR = 1.51, 95% CI = 1.17-1.96; P = .001), pseudoparkinsonism (OR = 1.66, 95% CI = 1.02-2.69; P = .008), prolactin (OR = 2.15, 95% CI = 1.34-3.43; P = .001) and severity of illness (OR = 1.34, 95% CI = 1.03-1.75; P = .030).Conclusion: Sexual dysfunction is prevalent among patients with schizophrenia spectrum disorder receiving either typical or atypical antipsychotics.","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":" ","pages":"373-392"},"PeriodicalIF":1.1000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence and correlates of sexual dysfunction among patients with schizophrenia spectrum disorder on antipsyhotic medications in Maiduguri, Northeastern Nigeria.\",\"authors\":\"Falmata Baba Shettima, Musa Abba Wakil, Taiwo Lateef Sheikh, Mohammed Abdulaziz, Isa Bukar Rabbebe, Ibrahim Abdu Wakawa, Ogualili Placidus\",\"doi\":\"10.1177/00912174231196612\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objectives: Despite the importance of a satisfying sexual life, most patients with schizophrenia spectrum disorders do not discuss sexual issue with their clinicians. The current study seeks to determine the prevalence and socio-clinical correlates of sexual dysfunction among patients with schizophrenia spectrum disorders receiving typical and atypical antipsychotic medications. The second objective is to determine the frequency and correlates of specific sexual dysfunction (desire, arousal, erection/lubrication and orgasm) by gender and drug type using the Arizona Sexual Experience Scale.Methodology: This cross-sectional study used standardized structured interviewer based survey to assess sexual dysfunction among patients with schizophrenia that are both sexually active and inactive at a tertiary hospital in Maiduguri from December 2020 to April 2021. Participants were also assayed for prolactin using ELISA Kit for a possible association with sexual dysfunction.Results: The overall prevalence of sexual dysfunction among patients with schizophrenia spectrum disorder receiving antipsychotics was 34% with patients on typical and atypical antipsychotics reporting rates of 36.8% and 24.6%, respectively. Among the typical and atypical antipsychotics, patients receiving haloperidol (40.3%) and risperidone (37.5%) reported a relatively higher frequency of sexual dysfunction compared to those receiving clozapine (18.2%). Independent correlates of sexual dysfunction were: female gender (OR = 1.89, 95% CI = 1.17-3.06; P = .010), being unmarried (OR = 1.51, 95% CI = 1.17-1.96; P = .001), pseudoparkinsonism (OR = 1.66, 95% CI = 1.02-2.69; P = .008), prolactin (OR = 2.15, 95% CI = 1.34-3.43; P = .001) and severity of illness (OR = 1.34, 95% CI = 1.03-1.75; P = .030).Conclusion: Sexual dysfunction is prevalent among patients with schizophrenia spectrum disorder receiving either typical or atypical antipsychotics.\",\"PeriodicalId\":50294,\"journal\":{\"name\":\"International Journal of Psychiatry in Medicine\",\"volume\":\" \",\"pages\":\"373-392\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Psychiatry in Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00912174231196612\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/8/24 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Psychiatry in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00912174231196612","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 0

摘要

目的：尽管满意的性生活非常重要，但大多数精神分裂症谱系障碍患者并不与临床医生讨论性问题。本研究旨在确定接受典型和非典型抗精神病药物治疗的精神分裂症谱系障碍患者中性功能障碍的发生率和社会临床相关性。第二个目标是使用亚利桑那性体验量表（Arizona Sexual Experience Scale）按性别和药物类型确定特定性功能障碍（欲望、唤起、勃起/润滑和性高潮）的频率和相关性：这项横断面研究采用了标准化的结构化访谈调查，以评估 2020 年 12 月至 2021 年 4 月期间迈杜古里一家三级医院中性生活活跃和不活跃的精神分裂症患者的性功能障碍情况。此外，还使用酶联免疫吸附试剂盒对参与者进行了催乳素检测，以确定其是否与性功能障碍有关：在接受抗精神病药物治疗的精神分裂症谱系障碍患者中，性功能障碍的总患病率为34%，典型和非典型抗精神病药物患者的患病率分别为36.8%和24.6%。在典型和非典型抗精神病药物中，与氯氮平（18.2%）相比，氟哌啶醇（40.3%）和利培酮（37.5%）患者出现性功能障碍的频率相对较高。性功能障碍的独立相关因素包括：女性（OR = 1.89，95% CI = 1.17-3.06；P = .010）、未婚（OR = 1.51，95% CI = 1.17-1.96；P = .001）、假性帕金森病（OR = 1.66，95% CI = 1.02-2.69；P = .008）、催乳素（OR = 2.15，95% CI = 1.34-3.43；P = .001）和病情严重程度（OR = 1.34，95% CI = 1.03-1.75；P = .030）：性功能障碍在接受典型或非典型抗精神病药物治疗的精神分裂症谱系障碍患者中很普遍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prevalence and correlates of sexual dysfunction among patients with schizophrenia spectrum disorder on antipsyhotic medications in Maiduguri, Northeastern Nigeria.

Objectives: Despite the importance of a satisfying sexual life, most patients with schizophrenia spectrum disorders do not discuss sexual issue with their clinicians. The current study seeks to determine the prevalence and socio-clinical correlates of sexual dysfunction among patients with schizophrenia spectrum disorders receiving typical and atypical antipsychotic medications. The second objective is to determine the frequency and correlates of specific sexual dysfunction (desire, arousal, erection/lubrication and orgasm) by gender and drug type using the Arizona Sexual Experience Scale.

Methodology: This cross-sectional study used standardized structured interviewer based survey to assess sexual dysfunction among patients with schizophrenia that are both sexually active and inactive at a tertiary hospital in Maiduguri from December 2020 to April 2021. Participants were also assayed for prolactin using ELISA Kit for a possible association with sexual dysfunction.

Results: The overall prevalence of sexual dysfunction among patients with schizophrenia spectrum disorder receiving antipsychotics was 34% with patients on typical and atypical antipsychotics reporting rates of 36.8% and 24.6%, respectively. Among the typical and atypical antipsychotics, patients receiving haloperidol (40.3%) and risperidone (37.5%) reported a relatively higher frequency of sexual dysfunction compared to those receiving clozapine (18.2%). Independent correlates of sexual dysfunction were: female gender (OR = 1.89, 95% CI = 1.17-3.06; P = .010), being unmarried (OR = 1.51, 95% CI = 1.17-1.96; P = .001), pseudoparkinsonism (OR = 1.66, 95% CI = 1.02-2.69; P = .008), prolactin (OR = 2.15, 95% CI = 1.34-3.43; P = .001) and severity of illness (OR = 1.34, 95% CI = 1.03-1.75; P = .030).

Conclusion: Sexual dysfunction is prevalent among patients with schizophrenia spectrum disorder receiving either typical or atypical antipsychotics.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Psychiatry in Medicine 医学-精神病学

CiteScore

3.00

自引率

5.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The International Journal of Psychiatry in Medicine (IJPM) bridges the gap between clinical psychiatry research and primary care clinical research. Providing a forum for addressing: The relevance of psychobiological, psychological, social, familial, religious, and cultural factors in the development and treatment of illness; the relationship of biomarkers to psychiatric symptoms and syndromes in primary care...